Skip to main content

Sequenom's Q2 Loss Narrows 35 Percent as Revenue Rises and R&D Spend Drops

NEW YORK (GenomeWeb News) – Sequenom today said second-quarter net loss narrowed on a 15-percent increase in revenues and reduced R&D spending.
 
The results caused shares in the company to trade up 6.9  percent, or $.11, at $1.70 mid-afternoon today.
 
Receipts for the three months ended June 30 increased to $7 million from $6 million year over year.
 
R&D costs declined almost 20 percent to $2.4 million from $3 million from the comparable quarter a year ago.
 
Sequenom said net loss shrank 35 percent to $4 million for the second quarter compared to $6 million last year.
 
Sequenom had $32.6 million in cash and cash equivalents as of June 30. The cash on hand includes the net proceeds of approximately $30 million from a private placement of common stock in June.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.